These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 17000695)

  • 1. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
    Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
    Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells.
    Yemelyanov A; Gasparian A; Lindholm P; Dang L; Pierce JW; Kisseljov F; Karseladze A; Budunova I
    Oncogene; 2006 Jan; 25(3):387-98. PubMed ID: 16170348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
    Li Y; Ahmed F; Ali S; Philip PA; Kucuk O; Sarkar FH
    Cancer Res; 2005 Aug; 65(15):6934-42. PubMed ID: 16061678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
    Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
    Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
    Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
    Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of NF-κB-related proteins and their modulation during TNF-α-provoked apoptosis in prostate cancer cells.
    Rodríguez-Berriguete G; Fraile B; Paniagua R; Aller P; Royuela M
    Prostate; 2012 Jan; 72(1):40-50. PubMed ID: 21520161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.
    Uzzo RG; Crispen PL; Golovine K; Makhov P; Horwitz EM; Kolenko VM
    Carcinogenesis; 2006 Oct; 27(10):1980-90. PubMed ID: 16606632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.
    Shaikh IA; Brown I; Schofield AC; Wahle KW; Heys SD
    Prostate; 2008 Nov; 68(15):1635-46. PubMed ID: 18668525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Pinto AC; Moreira JN; Simões S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
    Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
    BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
    BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
    Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.